BioLineRx annual current ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Current Ratio Growth & History (BLRX)
BioLineRx's current ratio was 1.95 for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.95 | 0.19 | +11.03% |
| 2024 | 2024-12-31 | 1.76 | 0.66 | +59.53% |
| 2023 | 2023-12-31 | 1.10 | −3.77 | −77.35% |
| 2022 | 2022-12-31 | 4.87 | −1.04 | −17.56% |
| 2021 | 2021-12-31 | 5.91 | 3.76 | +174.69% |
| 2020 | 2020-12-31 | 2.15 | −0.21 | −8.78% |
| 2019 | 2019-12-31 | 2.36 | −2.38 | −50.24% |
| 2018 | 2018-12-31 | 4.74 | −2.76 | −36.79% |
| 2017 | 2017-12-31 | 7.49 | −2.37 | −24.00% |
| 2016 | 2016-12-31 | 9.86 | — | — |
BioLineRx quarterly current ratio
Q4.16
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.20 | −0.86 | −41.94% |
| Q1 2026 | 2026-03-31 | 1.58 | −0.69 | −30.37% |
| Q4 2025 | 2025-12-31 | 1.95 | 0.19 | +11.03% |
| Q3 2025 | 2025-09-30 | 2.09 | — | — |
| Q2 2025 | 2025-06-30 | 2.06 | 0.45 | +27.91% |
| Q1 2025 | 2025-03-31 | 2.27 | — | — |
| Q4 2024 | 2024-12-31 | 1.76 | 0.66 | +59.53% |
| Q2 2024 | 2024-06-30 | 1.61 | −1.18 | −42.26% |
| Q4 2023 | 2023-12-31 | 1.10 | −3.77 | −77.35% |
| Q2 2023 | 2023-06-30 | 2.79 | −1.79 | −39.12% |
| Q4 2022 | 2022-12-31 | 4.87 | −1.04 | −17.56% |
| Q2 2022 | 2022-06-30 | 4.58 | −2.18 | −32.30% |
| Q4 2021 | 2021-12-31 | 5.91 | 3.76 | +174.69% |
| Q2 2021 | 2021-06-30 | 6.76 | 4.36 | +181.47% |
| Q4 2020 | 2020-12-31 | 2.15 | −0.21 | −8.78% |
| Q2 2020 | 2020-06-30 | 2.40 | −1.83 | −43.20% |
| Q4 2019 | 2019-12-31 | 2.36 | −2.38 | −50.24% |
| Q2 2019 | 2019-06-30 | 4.23 | −3.79 | −47.24% |
| Q4 2018 | 2018-12-31 | 4.74 | −2.76 | −36.79% |
| Q2 2018 | 2018-06-30 | 8.02 | — | — |
| Q4 2017 | 2017-12-31 | 7.49 | −2.37 | −24.00% |
| Q4 2016 | 2016-12-31 | 9.86 | — | — |
BioLineRx current ratio trends
Over the last five fiscal years, BioLineRx's current ratio decreased from 2.15 to 1.95, a change of −0.20. The latest reported quarter, Q2 2026, shows 1.20.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗